Alkem Laboratories Limited

BSE:539523 Stock Report

Market Cap: ₹598.3b

Alkem Laboratories Past Earnings Performance

Past criteria checks 5/6

Alkem Laboratories has been growing earnings at an average annual rate of 7.6%, while the Pharmaceuticals industry saw earnings growing at 14.9% annually. Revenues have been growing at an average rate of 11.4% per year. Alkem Laboratories's return on equity is 15.4%, and it has net margins of 12.5%.

Key information

7.6%

Earnings growth rate

7.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate11.4%
Return on equity15.4%
Net Margin12.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Alkem Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:539523 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23126,34415,73230,3940
30 Sep 23123,51414,32929,9260
30 Jun 23119,90611,43330,0810
31 Mar 23115,9939,84229,7260
31 Dec 22111,80510,20827,0810
30 Sep 22107,58610,91726,5360
30 Jun 22104,79213,05125,7720
31 Mar 22106,34216,45625,7690
31 Dec 21103,42517,78022,6600
30 Sep 21100,41617,03322,0480
30 Jun 2196,04416,31121,1830
31 Mar 2188,65015,85019,8070
31 Dec 2087,21815,33821,2170
30 Sep 2085,97114,64821,0760
30 Jun 2084,98413,63620,8920
31 Mar 2083,44411,27120,8530
31 Dec 1981,48411,05720,3470
30 Sep 1978,9299,26219,8550
30 Jun 1975,4788,09819,2370
31 Mar 1973,5727,60518,7280
31 Dec 1870,1576,60217,7620
30 Sep 1868,3186,29317,4120
30 Jun 1867,7886,95517,2120
31 Mar 1863,9186,30916,5550
31 Dec 1760,0447,00915,1020
30 Sep 1757,2857,62614,6990
30 Jun 1755,0197,24814,2450
31 Mar 1756,8758,92013,9100
31 Dec 1656,9337,73213,4970
30 Sep 1654,9927,26712,9770
30 Jun 1652,4197,1089,4300
31 Mar 1649,2487,41611,6990
31 Dec 1547,9758,18915,267220
30 Sep 1544,5567,22715,252291
30 Jun 1540,4595,78111,940150
31 Mar 1537,4343,9169,0320
31 Mar 1431,1914,35310,466210
31 Mar 1324,9243,8388,578115

Quality Earnings: 539523 has high quality earnings.

Growing Profit Margin: 539523's current net profit margins (12.5%) are higher than last year (9.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 539523's earnings have grown by 7.6% per year over the past 5 years.

Accelerating Growth: 539523's earnings growth over the past year (54.1%) exceeds its 5-year average (7.6% per year).

Earnings vs Industry: 539523 earnings growth over the past year (54.1%) exceeded the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: 539523's Return on Equity (15.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.